T0	Participants 123 157	patients with chronic hepatitis C.
T1	Participants 194 268	Hepatitis C Antiviral Long-Term Treatment against Cirrhosis (HALT-C) Trial
T2	Participants 340 409	patients with chronic hepatitis C and advanced fibrosis or cirrhosis.
T3	Participants 595 724	total of 517 HALT-C patients received peginterferon alfa-2a (90 microg/week); 532 received no additional treatment for 3.5 years.
T4	Participants 944 977	Patients with cirrhosis (n = 427)
T5	Participants 1046 1079	patients with fibrosis (n = 622).
T6	Participants 1734 1781	in men, sexual health in a large patient cohort